Koru Medical Systems (KRMD) late Thursday disclosed plans to begin a late-stage trial for a new indication of an existing commercialized drug therapy through a collaboration with an unnamed pharmaceutical manufacturer to evaluate the safety, efficacy and performance of the drug for treating patients with a rare renal disorder following kidney transplants.

Koru shares recently were climbing about 1% in extended session.